文献速递银屑病与炎症性皮肤病

测量银屑病关节炎症状:银屑病临床试验中的核心领域

Measuring psoriatic arthritis symptoms: A core domain in psoriasis clinical trials.
PubMed 文献 · J Am Acad Dermatol · 2019-06-01

国际皮肤科结局测量组织要求所有银屑病试验测量银屑病关节炎(PsA)症状。本研究通过共识构建流程,包括文献回顾、预德尔菲、德尔菲调查和共识会议,确定PsA筛查方法和最适合的症状测量工具。结果显示,87.5%的德尔菲专家同意所有银屑病试验患者应使用经验证的筛查工具筛查PsA,首选测量工具为PsAID9,RAPID3为可接受的替代方案。

要点

  • 所有银屑病临床试验患者均应使用经验证的工具筛查PsA。
  • PsA症状测量首选PsAID9,RAPID3为可接受的替代。
  • 共识基于国际皮肤科结局测量组织(IDEOM)的推荐。

核心结论

  • 绝大多数专家利益相关者同意所有银屑病试验参与者应筛查PsA,并使用PsAID9(或RAPID3)测量PsA症状。

研究设计与样本

  • 共识构建研究,遵循COSMIN、COMET和OMERACT指南,包括文献回顾和质量评估、预德尔菲练习、德尔菲调查和共识会议,参与者包括患者、医生、行业伙伴和患者协会代表。

主要发现

  • 在德尔菲调查的297名专家参与者中,87.5%同意所有银屑病试验患者应使用经验证的筛查工具筛查PsA。
  • 关于PsA症状测量,首选工具为Psoriatic Arthritis Impact of Disease-9(PsAID9),Routine Assessment Patient Index Data-3(RAPID3)为可接受的替代。

关键数值与推荐

  • 87.5%的德尔菲专家同意所有银屑病试验患者应筛查PsA。
  • PsA症状测量首选PsAID9,RAPID3为可接受的替代。

临床怎么用

  • 在银屑病临床试验中,应使用经验证的工具筛查所有患者的PsA,并采用PsAID9(或RAPID3)测量PsA症状。

局限性

  • 仅国际皮肤科结局测量组织成员参与了共识会议。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The International Dermatology Outcome Measures established a set of core domains to be measured in all psoriasis trials. This set requires that symptoms of psoriatic arthritis (PsA) be measured in all psoriasis studies. OBJECTIVE: To identify the approach to PsA screening and the most appropriate outcome measure for capturing PsA symptoms. METHODS: Following guidelines (ie, the COnsensus-based Standards for the selection of health Measurement INstruments, Core Outcome Measures in Effectiveness Trials Initiative, and Outcome Measures in Rheumatology Handbook), we conducted a consensus-building study that included patients, physicians, industry partners, and patient association representatives. The process consisted of a literature review and quality appraisal of measures for PsA symptoms, a pre-Delphi exercise, a Delphi survey, and a consensus meeting. RESULTS: Among the 297 expert participants in the Delphi survey, 87.5% agreed that all patients in a psoriasis trial should be screened for PsA with a validated screening tool. Regarding the measurement of PsA symptoms, the preferred instrument was the Psoriatic Arthritis Impact of Disease-9 (PsAID9), with the Routine Assessment Patient Index Data-3 (RAPID3) representing an acceptable alternative. LIMITATIONS: Only International Dermatology Outcome Measures members participated in the consensus meeting. CONCLUSION: The overwhelming majority of expert stakeholders agreed that all psoriasis trial participants should be screened for PsA, with PsA symptoms measured by using PsAID9 (or alternatively with RAPID3).

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Perez-Chada LM, Gottlieb AB, Cohen J, et al. Measuring psoriatic arthritis symptoms: A core domain in psoriasis clinical trials. J Am Acad Dermatol. 2019. PMID: 31163240. doi:10.1016/j.jaad.2019.05.075

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。